The Optispan Podcast with Matt Kaeberlein

NEW PEARL Trial Results: Your Questions Answered on Aging with Rapamycin for Longevity | 66 - AMA #5

Sep 19, 2024
Discover the latest findings from the PEARL trial, a groundbreaking study on rapamycin's potential to combat aging. Explore innovative dosing strategies, including an eight-on, four-off regimen, aimed at maximizing longevity. Delve into the differences between rapamycin and Everolimus, as well as the nuances in their effects on aging. Unpack the complexities and costs of conducting longevity trials, and learn why functional measures might be more effective than direct aging reversal metrics. Get ready for a captivating deep dive into the science of aging!
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

Compounded Rapamycin Lower Bioavailability

  • The PEARL trial used compounded rapamycin with about 28-29% of the bioavailability of generic tablets.
  • This significantly lowered the effective dose participants actually received compared to intended dosing.
ADVICE

Measure Rapamycin Blood Levels

  • Use the LabCorp sirolimus blood test to quantitatively measure rapamycin levels.
  • It's sensitive enough for most off-label clinical monitoring and not very expensive.
INSIGHT

Possible Sex Differences in Rapamycin Response

  • Women in the PEARL trial showed better body composition responses to rapamycin, suggesting possible sex differences.
  • Optimal dosing may differ by sex, but individual variability is likely more important than sex alone.
Get the Snipd Podcast app to discover more snips from this episode
Get the app